Technical Analysis for GWPH - GW Pharmaceuticals Plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
113.95 | 4.19% | 4.58 |
GWPH closed up 4.19 percent on Monday, August 10, 2020, on 1.96 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical GWPH trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Fell Below 200 DMA | Bearish | 4.19% | |
| Fell Below 50 DMA | Bearish | 4.19% | |
| MACD Bearish Centerline Cross | Bearish | 4.19% | |
| Expansion Breakdown | Bearish Swing Setup | 4.19% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/04/2020
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
GW Pharmaceuticals plc, together with its subsidiaries, engages in the research, development, and commercialization of a range of cannabinoid prescription medicines. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in treatment of cancer pain. In addition, the company has two product candidates in Phase II trials in the field of diabetes and inflammation, as well as pre-clinical research programmes evaluating the use of selected cannabinoids for the treatment of glioma, epilepsy, and psychiatric illness. It has a strategic alliance with Otsuka Pharmaceutical Co. Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.
Health Cancer Pharmaceutical Industry Pain Drugs Treatment Of Cancer Diabetes Medication Inflammation Pharmaceuticals Policy Cannabis Epilepsy Glioma Cannabinoids Neuropathic Pain
Health Cancer Pharmaceutical Industry Pain Drugs Treatment Of Cancer Diabetes Medication Inflammation Pharmaceuticals Policy Cannabis Epilepsy Glioma Cannabinoids Neuropathic Pain
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 158.255 |
| 52 Week Low | 67.98 |
| Average Volume | 335,728 |
| 200-Day Moving Average | 112.62 |
| 50-Day Moving Average | 128.03 |
| 20-Day Moving Average | 130.51 |
| 10-Day Moving Average | 126.89 |
| Average True Range | 6.39 |
| ADX | 20.15 |
| +DI | 15.80 |
| -DI | 35.97 |
| Chandelier Exit (Long, 3 ATRs ) | 122.82 |
| Chandelier Exit (Short, 3 ATRs ) | 126.16 |
| Upper Bollinger Band | 145.60 |
| Lower Bollinger Band | 115.43 |
| Percent B (%b) | -0.05 |
| BandWidth | 23.12 |
| MACD Line | -1.72 |
| MACD Signal Line | 0.37 |
| MACD Histogram | -2.092 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 118.75 | ||||
| Resistance 3 (R3) | 118.39 | 116.42 | 117.95 | ||
| Resistance 2 (R2) | 116.42 | 115.20 | 116.61 | 117.68 | |
| Resistance 1 (R1) | 115.19 | 114.45 | 115.81 | 115.55 | 117.42 |
| Pivot Point | 113.22 | 113.22 | 113.53 | 113.41 | 113.22 |
| Support 1 (S1) | 111.99 | 112.00 | 112.61 | 112.35 | 110.48 |
| Support 2 (S2) | 110.02 | 111.25 | 110.21 | 110.22 | |
| Support 3 (S3) | 108.79 | 110.02 | 109.95 | ||
| Support 4 (S4) | 109.15 |
